#1 Clinical Trials Search in Europe

Study on the Safety and Effectiveness of Sargramostim with Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone in Untreated Light Chain Amyloidosis Patients

2 1 1 1

What is this study about?

This clinical trial is focused on studying a condition called Light Chain Amyloidosis, which is a rare disease where abnormal proteins called amyloids build up in organs like the heart and kidneys, leading to their failure. The study will use a combination of treatments known as D-VCd Therapy, which includes the medications Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone. Additionally, a substance called Sargramostim will be used. Sargramostim is known to help the body produce more white blood cells and may assist in breaking down amyloid deposits.

The purpose of this study is to evaluate how effective and safe this combination of treatments is for patients who have not yet received treatment for Light Chain Amyloidosis. Participants in the study will receive these medications and be monitored for their response to the treatment and any side effects they may experience. The study aims to see if the treatment can lead to a complete response in the blood and improve the function of affected organs.

The study will take place over a period of time, during which participants will receive the treatment and undergo regular check-ups to assess their health and the progress of the disease. The goal is to determine if this combination of treatments can provide a better outcome for patients with Light Chain Amyloidosis by reducing the amyloid deposits and improving organ function.

1 initial assessment

Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes a review of medical history and a series of tests to ensure the patient meets the study criteria.

2 treatment initiation

The treatment begins with the administration of a combination therapy known as D-VCd, which includes the medications daratumumab, cyclophosphamide, bortezomib, and dexamethasone.

Daratumumab is given as a subcutaneous injection at a dose of 1800 mg.

Cyclophosphamide is administered orally in the form of coated tablets.

Bortezomib is provided as a subcutaneous injection.

Dexamethasone is taken orally in tablet form at a dose of 20 mg.

3 ongoing treatment

The treatment regimen is repeated in cycles. Each cycle lasts for a specified period, during which the medications are administered according to the study protocol.

Regular monitoring is conducted to assess the patient’s response to the treatment and to manage any side effects.

4 additional medication

In addition to the D-VCd therapy, sargramostim is used to support the treatment. Sargramostim is a medication that helps stimulate the production of white blood cells and is administered as an injection.

5 evaluation and follow-up

Throughout the study, evaluations are conducted to measure the effectiveness of the treatment. This includes assessing the percentage of patients who achieve a complete hematologic response.

Safety assessments are also performed to monitor for any serious adverse events.

6 completion of study

The study is expected to conclude by September 2026. At the end of the study, a final assessment is conducted to evaluate the overall outcomes and the patient’s health status.

Who Can Join the Study?

  • You must be 18 years of age or older.
  • You or your legal representative must sign an informed consent form. This means you understand the study and agree to participate.
  • You need a diagnosis of AL amyloidosis. This is confirmed by finding specific materials in tissue samples using special tests.
  • You must have measurable disease of AL amyloidosis. This means certain levels of proteins in your blood are present, which can be measured.
  • One or more of your organs must be affected by AL amyloidosis.
  • Your performance status should be 0, 1, or 2 on the ECOG scale. This scale measures how well you can perform daily activities.
  • Your blood test results must meet specific criteria, such as having enough white blood cells, red blood cells, and platelets.
  • If you are a woman who can have children, you must have a negative pregnancy test and agree to use reliable birth control during the study and for a certain period after.
  • If you are a woman, you must agree not to donate eggs during the study and for a certain period after.
  • If you are a man, you must agree to use birth control if you are sexually active with a woman who can have children. You must also agree not to donate sperm during the study and for a certain period after.

Who Cannot Join the Study?

  • Patients who have a different type of amyloidosis other than AL amyloidosis. AL amyloidosis is a condition where abnormal proteins called amyloid fibrils build up in organs like the heart or kidneys.
  • Patients who have received any other treatment for AL amyloidosis within a certain period before the study starts.
  • Patients with severe heart problems that are not stable or controlled.
  • Patients with severe kidney problems that are not stable or controlled.
  • Patients with active infections that require treatment.
  • Patients who have had another type of cancer within the last five years, except for certain skin cancers or other specific conditions.
  • Patients who are pregnant or breastfeeding.
  • Patients who have a known allergy to any of the study medications or their ingredients.
  • Patients who have participated in another clinical trial within a certain period before this study.
  • Patients with any other medical condition that the study doctors believe would make it unsafe for them to participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego Warsaw Poland
Wolqrrcwqmx Wyfypadgaylcjwehfzfb Cdlltqj Oxfpfeqlo I Tnihofjnqanuu Is Mqhswmcdffp W Lwnfb Lodz Poland
Ualdyqfcstl Mwbehuen Isv Kpjbsj Mfxogkivwojlkaq W Ppkfeihq Poznan Poland
Nxccmgwz Iqbzvyjp Ojbimjzwn Izi Mkkap Sfjxsyhdmbxhkwoyfgbhkmbvkinu Ihxosmnm Bmwhivff Cracow Poland
Udcjcpeezwxdzj Caagpjv Krahfjlur Gdansk Poland

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Poland Poland
Not recruiting
01.04.2023

Trial locations

Investigated drugs:

Sargramostim is a medication used to stimulate the production of white blood cells. It helps the body fight infections and recover from treatments that can lower white blood cell counts.

Daratumumab is a medication used to treat certain types of blood disorders. It works by targeting and destroying specific cells in the immune system that are involved in the disease process.

Cyclophosphamide is a chemotherapy drug that helps to slow or stop the growth of cancer cells. It is used in combination with other medications to treat various types of cancer and blood disorders.

Bortezomib is a medication that interferes with the growth of cancer cells and slows their spread in the body. It is used to treat certain types of blood cancers.

Dexamethasone is a steroid that helps reduce inflammation and suppresses the immune system. It is often used in combination with other medications to treat a variety of conditions, including certain types of cancer and blood disorders.

Light Chain Amyloidosis – This disease is a type of plasma cell disorder where misfolded immunoglobulin light chains form amyloid fibrils. These fibrils deposit in various organs, most commonly the heart and kidneys, leading to their dysfunction. The accumulation of these deposits can cause significant organ damage over time. The disease is part of a larger group of conditions known as amyloidoses, which are characterized by abnormal protein deposits. The progression involves the continuous buildup of amyloid fibrils, which can eventually lead to organ failure if not managed.

Trial ID:
2024-518658-18-00
Protocol code:
STARLIGHT
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study on Safe Skin Test Concentrations for Biotherapy Allergies in Patients with Cancer Using Atezolizumab, Daratumumab, and Nivolumab

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Safety and Effectiveness of Linvoseltamab, Sarilumab, and Dexamethasone in Adults with Relapsed or Refractory AL Amyloidosis

    Recruiting

    1 1 1 1
    Investigated drugs:
    Greece Spain